‘s () (FRA:H5O) (LON:MXC) Co-founder and MD Roby Zomer joins Proactive London to explain why the company has chosen to list on the London Stock Exchange (LSE) on Tuesday, February 9.
This move will mean the firm will become the first medicinal cannabis company to be admitted to the main market.
This follows a strongly supported £6.5 million share placement led by leading UK institutional fund managers and supported by UK family office and professional high net worth investors.
Read More: MGC Pharmaceuticals get set for LSE debut as first medicinal cannabis company